TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05244473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: Daily use of a combination of HIV medicines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ART
Description: Daily use of a combination of HIV medicines
Study: NCT04050189

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Natural products: Probiotics
Description: Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Natural products: Probiotics
Description: Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
Study: NCT03495479

Intervention type: DRUG
Intervention: OMN54
Description: Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
Study: NCT04050189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
Study: NCT06422052

Intervention type: OTHER
Intervention: Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）
Description: H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
Study: NCT05636358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based hypnotherapy
Description: The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
Study: NCT05067478

Intervention type: DRUG
Intervention: Vibegron
Description: Vibegron to be administered.

Intervention type: DRUG
Intervention: Vibegron
Description: Vibegron to be administered.
Study: NCT06128681

Intervention type: PROCEDURE
Intervention: Intraairway ultrasound-guided mediastinal opening technique
Description: Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses
Study: NCT06496932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listen to music
Description: Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
Study: NCT05222191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
Study: NCT05183490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapidly generated virus specific T (R-MVST) cells
Description: The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapidly generated virus specific T (R-MVST) cells
Description: The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg
Study: NCT06167668

Intervention type: OTHER
Intervention: the routine chronic disease management mode
Description: indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged

Intervention type: OTHER
Intervention: the family-centered family enabling health management mode
Description: The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
Study: NCT05080569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Vaginal Product
Description: 3dd200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3dd1 vaginal capsule
Study: NCT06326515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Reduction and Relapse Management
Description: To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011).
Study: NCT05188573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early detection pancreatic cancer test
Description: Blood collection and pancreatic cancer early detection testing with return of results

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early detection pancreatic cancer test and MRI Imaging
Description: Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
Study: NCT05987839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic system
Description: Total knee arthroplasty assisted by knee navigation and positioning system
Study: NCT05307120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diameter integrated in secondary diabetes care
Description: Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
Study: NCT05113212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macular surgery with NGENUITY surgical display system
Description: Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macular surgery with standard operating microscope
Description: Patient undergoes VR surgery with visualization using standard operating microscope
Study: NCT05312190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZhenQi BuXue KouFuYe
Description: Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZhenQi BuXue KouFuYe
Description: Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Capsules
Description: The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Capsules
Description: The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
Study: NCT05903118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBMRNA-176
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBMRNA-176
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT04895202

Intervention type: OTHER
Intervention: Siponimod
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05819983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: Ivermectin 200µg/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: Ivermectin 200µg/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Cream
Description: Permethrin cream 5%
Study: NCT05990075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
Study: NCT05624229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors
Description: PPI infusion continued to use for 5 days in experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No Proton Pump Inhibitors
Description: PPI infusion stopped in standard group after endoscopy.
Study: NCT06647108

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food Supplement
Description: The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06647147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercises
Description: From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercises
Description: From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
Study: NCT05165303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine with propofol
Description: different concentrations of lidocaine added to propofol varying from
Study: NCT05246618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUM012
Description: Ex-vivo infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ex-vivo infusion
Study: NCT04837235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: oral
Study: NCT06647368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET with 18-FDG
Description: The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
Study: NCT06645782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual, Group CF-CBT
Description: Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
Study: NCT06209411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Testing
Description: Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Based Screening
Description: Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
Study: NCT05823051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VASIDS-TP and Counseling Practice
Description: VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
Study: NCT05961488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary Calcium Score and Coronary CT angiogram
Description: Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
Study: NCT06013644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needle
Description: a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needle
Description: a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
Study: NCT05707533

Intervention type: PROCEDURE
Intervention: TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique
Description: The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
Study: NCT06109441

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALTB-268
Description: ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
Study: NCT06580509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
Study: NCT06392659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Tablets for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsules for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for Oral Administration.
Study: NCT05456178

Intervention type: OTHER
Intervention: Electrostatic wipe
Description: The main objective will be to study the feasibility of the quantification of domestic fungal exposure with electrostatic wipe. The interval of environmental fungal exposure quantification values measured by conventional mycology and by NGS will be established, with analysis of the correlation between the quantification obtained by the two techniques.~For this, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks. The wipes will be analyzed by the mycology laboratory of the Croix Rousse hospital.
Study: NCT06431282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser + HA
Description: Probands will be treated with a CO2 laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thulium laser + HA
Description: Probands will be treated with a thulium laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
Study: NCT05875415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
Description: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
Description: Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
Study: NCT05574426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Breaks
Description: Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Movement Breaks
Description: Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.